108 related articles for article (PubMed ID: 3152918)
41. No preferential sensitivity of clonogenic AML cells to ASTA-Z-7557.
Kluin-Nelemans HC; Martens AC; Löwenberg B; Hagenbeek A
Leuk Res; 1984; 8(4):723-8. PubMed ID: 6590937
[TBL] [Abstract][Full Text] [Related]
42. Toxicity of ASTA Z 7557 (INN mafosfamide) to normal- and leukemic stem cells: implications for autologous bone marrow transplantation.
Hagenbeek A; Martens AC
Invest New Drugs; 1984; 2(2):237-43. PubMed ID: 6381383
[TBL] [Abstract][Full Text] [Related]
43. The effects of acetaldophosphamide, a novel stable aldophosphamide analogue, on normal human and leukemic progenitor cells in vitro: implications for use in bone marrow purging.
Beran M; Andersson BS; Wang Y; McCredie KB; Farquhar D
Cancer Res; 1988 Jan; 48(2):339-45. PubMed ID: 3275495
[TBL] [Abstract][Full Text] [Related]
44. Use and mechanism of action of AS101 in protecting bone marrow colony forming units-granulocyte-macrophage following purging with ASTA-Z 7557.
Kalechman Y; Barkai IS; Albeck M; Horwith G; Sehagl SN; Sredni B
Cancer Res; 1991 Oct; 51(20):5614-20. PubMed ID: 1913679
[TBL] [Abstract][Full Text] [Related]
45. Preclinical studies of the combination of mafosfamide (Asta-Z 7654) and etoposide (VP-16-213) for purging leukemic autologous marrow.
Tamayo E; Hervé P
Exp Hematol; 1988 Feb; 16(2):97-101. PubMed ID: 3276544
[TBL] [Abstract][Full Text] [Related]
46. Progenitor cell numbers (CFU-GM, CFU-D, and CFU-Mix) and hemopoietic recovery following autologous marrow transplantation.
Stewart FM; Kaiser DL; Ishitani KP; Pirsch GW; Niskanen E
Exp Hematol; 1989 Oct; 17(9):974-80. PubMed ID: 2673831
[TBL] [Abstract][Full Text] [Related]
47. High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells.
Brunvand MW; Bensinger WI; Soll E; Weaver CH; Rowley SD; Appelbaum FR; Lilleby K; Clift RA; Gooley TA; Press OW; Fefer A; Storb R; Sanders JE; Martin PL; Chauncey T; Maziarz RT; Zuckerman N; Montgomery P; Dorn R; Weiden PL; Demirer T; Holmberg LA; Schiffman K; McSweeney PA; Buckner CD
Bone Marrow Transplant; 1996 Jul; 18(1):131-41. PubMed ID: 8832006
[TBL] [Abstract][Full Text] [Related]
48. In vitro marrow purging in chronic myelogenous leukemia: effect of mafosfamide and recombinant granulocyte--macrophage colony-stimulating factor.
Carlo-Stella C; Mangoni L; Piovani G; Almici C; Garau D; Caramatti C; Rizzoli V
Bone Marrow Transplant; 1991 Oct; 8(4):265-73. PubMed ID: 1756324
[TBL] [Abstract][Full Text] [Related]
49. Variability in 4-hydroperoxycyclophosphamide activity during clinical purging for autologous bone marrow transplantation.
Jones RJ; Zuehlsdorf M; Rowley SD; Hilton J; Santos GW; Sensenbrenner LL; Colvin OM
Blood; 1987 Nov; 70(5):1490-4. PubMed ID: 3311205
[TBL] [Abstract][Full Text] [Related]
50. The effect of a combined purging with mafosfamide and hyperthermia on murine haemopoietic stem cells and leukaemogenic cells.
Gidáli J; Fehér I
Bone Marrow Transplant; 1992 Dec; 10(6):479-83. PubMed ID: 1490197
[TBL] [Abstract][Full Text] [Related]
51. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma.
Advani R; Chao NJ; Horning SJ; Blume KG; Ahn DK; Lamborn KR; Fleming NC; Bonnem EM; Greenberg PL
Ann Intern Med; 1992 Feb; 116(3):183-9. PubMed ID: 1345803
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of lymphocyte subsets after autologous bone marrow transplantation with marrow treated by ASTA Z 7557 in acute leukemia: incidence of the in vitro treatment.
Le Blanc G; Douay L; Laporte JP; Dominh A; Deloux J; Najman A; Duhamel G; Gorin NC
Exp Hematol; 1986 Jun; 14(5):366-71. PubMed ID: 3519264
[TBL] [Abstract][Full Text] [Related]
53. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
[TBL] [Abstract][Full Text] [Related]
54. Hematopoietic recovery following autologous bone marrow transplantation: role of cryopreservation, number of cells infused and nature of high-dose chemotherapy.
Hartmann O; Beaujean F; Bayet S; Pico JL; Tournade MF; Lemerle ; Parmentier C
Eur J Cancer Clin Oncol; 1985 Jan; 21(1):53-60. PubMed ID: 3882431
[TBL] [Abstract][Full Text] [Related]
55. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization.
Passos-Coelho JL; Braine HG; Davis JM; Huelskamp AM; Schepers KG; Ohly K; Clarke B; Wright SK; Noga SJ; Davidson NE
J Clin Oncol; 1995 Mar; 13(3):705-14. PubMed ID: 7533827
[TBL] [Abstract][Full Text] [Related]
56. Increased yield of myeloid progenitor cells in bone marrow harvested for autologous transplantation by pretreatment with recombinant human granulocyte-colony stimulating factor.
Johnsen HE; Hansen PB; Plesner T; Jensen L; Gaarsdal E; Andersen H; Hansen SW; Birgens H; Jacobsen GK; Kjaersgaard E
Bone Marrow Transplant; 1992 Sep; 10(3):229-34. PubMed ID: 1384899
[TBL] [Abstract][Full Text] [Related]
57. Bone marrow purging with mafosfamide--a critical survey.
Sindermann H; Peukert M; Hilgard P
Blut; 1989 Nov; 59(5):432-41. PubMed ID: 2684298
[TBL] [Abstract][Full Text] [Related]
58. ASTA Z 7557 (INN mafosfamide) for the in vitro treatment of human leukemic bone marrows.
Douay L; Gorin NC; Laporte JP; Lopez M; Najman A; Duhamel G
Invest New Drugs; 1984; 2(2):187-90. PubMed ID: 6381382
[TBL] [Abstract][Full Text] [Related]
59. Prompt haemopoietic reconstitution following hyperthermia purged autologous marrow and peripheral blood stem cell transplantation in acute myeloid leukaemia.
Herrmann RP; O'Reilly J; Meyer BF; Lazzaro G
Bone Marrow Transplant; 1992 Sep; 10(3):293-5. PubMed ID: 1358379
[TBL] [Abstract][Full Text] [Related]
60. Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF.
Laughlin MJ; Kirkpatrick G; Sabiston N; Peters W; Kurtzberg J
Ann Hematol; 1993 Dec; 67(6):267-76. PubMed ID: 7506580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
